ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Order Full text via Infotrieve
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Svendsen, U.
Right arrow Articles by Jorgensen, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Svendsen, U.
Right arrow Articles by Jorgensen, H
Eur Respir J 1991; 4: 992-999
Copyright © ERS Journals Ltd 1991


Clinical Trial

Inhaled nedocromil sodium as additional treatment to high dose inhaled corticosteroids in the management of bronchial asthma

UG Svendsen and H Jorgensen

Thirty five asthmatic patients were included in a randomized, double-blind, placebo-controlled, parallel group study of inhaled nedocromil sodium (4 x 4 mg daily) as an additional treatment to high dose (greater than or equal to 1,000 micrograms) inhaled corticosteroids in the management of bronchial asthma. Following a four week baseline, patients received nedocromil sodium (17) or placebo treatment (18) for eight weeks. Five patients (four in the group subsequently randomized to nedocromil sodium) used short course oral corticosteroid therapy during the baseline and four placebo treated patients used oral steroid therapy during treatment. Fifteen patients (11 nedocromil sodium) reported unusual symptoms. Two nedocromil sodium treated patients were withdrawn owing to treatment taste and vomiting. Statistically significant treatment differences in favour of nedocromil sodium were seen for daytime symptoms (p = 0.03) and morning peak expiratory flow (PEF) (p = 0.012) during weeks 5-8, and for clinician opinion (p = 0.02). Patient opinion (p = 0.053) and evening PEF (p = 0.08) failed to reach statistical significance. Eight out of fifteen and three out of seventeen patients considered nedocromil sodium and placebo, respectively, to be very or moderately effective. The results indicate that the addition of nedocromil sodium (4 mg four times daily) to moderate to severe asthmatics not fully controlled on a regimen of greater than or equal to 1,000 micrograms inhaled corticosteroids and inhaled bronchodilators can produce improvements in symptoms and pulmonary function.


This article has been cited by other articles:


Home page
ChestHome page
J. W. Georgitis
The 1997 Asthma Management Guidelines and Therapeutic Issues Relating to the Treatment of Asthma
Chest, January 1, 1999; 115(1): 210 - 217.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
P. J. BARNES, S. PEDERSEN, and W. W. BUSSE
Efficacy and Safety of Inhaled Corticosteroids . New Developments
Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): S1 - 53.
[Full Text] [PDF]


Home page
NEJMHome page
M. Weinberger and L. Hendeles
Theophylline in Asthma
N. Engl. J. Med., May 23, 1996; 334(21): 1380 - 1388.
[Full Text] [PDF]


Home page
NEJMHome page
P. J. Barnes
Inhaled Glucocorticoids for Asthma
N. Engl. J. Med., March 30, 1995; 332(13): 868 - 875.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the European Respiratory Society.